Executive Summary

iSpecimen Inc. (Nasdaq: ISPC) has released its annual report for the fiscal year ended December 31, 2025. The company, a provider of biospecimen marketplace solutions, continues to face significant operational and financial challenges. This report contains several key disclosures, risks, and planned developments that investors and shareholders must be aware of, many of which could materially affect share value.

Key Points from the Report

• Continued Losses & Going Concern Doubts: iSpecimen has incurred losses since its inception and expects to continue incurring losses for the foreseeable future. The audited financial statements include an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern. Recurring net losses and accumulated deficits are significant, and continued operations depend on improved profitability and additional financing, which is not guaranteed.
• Material Weakness in Internal Controls: The company identified a material weakness in its internal controls over financial reporting during 2025, specifically relating to sales tax documentation and collection. Remediation measures are underway, including engaging external advisors and implementing new software, but effectiveness is not yet assured. Future material weaknesses could arise, possibly resulting in reporting failures or financial misstatements.
• Unpredictable Revenue Trends: Revenue remains highly unpredictable, impacting the company’s ability to forecast future results. Factors influencing this include customer demand, market conditions, and underlying research trends.
• Need for Additional Capital: iSpecimen will likely require substantial additional capital to fund business growth, technology development, and operational expansion. Failure to secure financing on favorable terms or at all may jeopardize ongoing operations.
• Technology Investment & Platform Development: The iSpecimen Marketplace platform is central to the company’s business model, with ongoing investments planned to improve scalability, functionality, and ease of use. In 2025, \$2.16 million was incurred in technology expenses, with \$1 million capitalized for software development.
• Risks from Cybersecurity & Data Protection: The business is subject to cybersecurity threats, including data breaches. Failure to comply with federal and state data protection regulations could result in fines, penalties, litigation, and reputational damage.
• Nasdaq Listing Risks: There is no assurance of continued compliance with Nasdaq listing standards. If the company fails to meet these requirements, shares could be delisted, substantially impacting liquidity and investor confidence.
• Potential Dilution: If additional capital is raised through equity, existing shareholders may face dilution. The company does not expect to pay dividends in the foreseeable future.
• Market Risks: General economic downturns, changes in research budgets, disease landscape shifts (e.g., COVID-19), and evolving biomarker research may impact demand for iSpecimen’s products and services.
• International Expansion Risks: Expansion into international markets exposes the company to challenges such as compliance with complex regulations, cultural differences, currency fluctuations, contract enforcement difficulties, and heightened risks of unethical practices.

Risks and Price-Sensitive Disclosures for Shareholders

• Going Concern Doubts: The explicit mention of “substantial doubt about ability to continue as a going concern” is highly price-sensitive and could trigger negative sentiment among investors, potentially leading to share price decline.
• Material Weakness in Internal Controls: The ongoing material weakness in financial controls, especially around sales tax collection and reporting, may result in future restatements or regulatory scrutiny, damaging investor confidence.
• Capital Requirements & Potential Dilution: The need for additional capital, paired with the risk of dilution, is critical for shareholders. Failure to secure financing could imperil operations, while raising new equity could dilute existing holdings.
• Nasdaq Listing Risks: Continued listing on Nasdaq is not assured. Delisting would severely limit liquidity and trading for shareholders.
• No Dividends Expected: Investors should not expect dividends; returns are dependent on share price appreciation.
• Unpredictable Revenue & Business Model Sustainability: Revenue unpredictability and the need for significant technology investment raise questions about the long-term viability of the business model.

Strategic Developments & Forward-Looking Statements

• Marketplace Enhancements: iSpecimen is investing in technology to scale its marketplace and position for new business lines (patient recruitment, data licensing). If successfully executed, this could open new revenue streams.
• Remediation Measures: The company has taken steps to address internal control weaknesses, which may improve compliance and reduce risk in the future.

Conclusion

iSpecimen’s 2025 Annual Report presents a company at a critical juncture, facing substantial financial and operational risks with uncertain prospects. The material weaknesses in internal controls, unpredictability of revenue, need for additional capital, and doubts about ongoing operations are all highly price-sensitive and may influence the share price. While technology investments and marketplace enhancements offer hope for future growth, shareholders should be prepared for possible volatility and dilution, and the risk of delisting from Nasdaq.